Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could loosen stiff arms after stroke

NCT ID NCT06783114

Symptom relief Sponsor: Chongqing Claruvis Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new injection called YY001 (a type of botulinum toxin) to reduce muscle stiffness in the arm or hand of adults who had a stroke. About 254 people will receive either the study drug or a placebo to see if it improves movement and daily tasks like dressing or hygiene. The goal is symptom relief, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 254 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 75 years old inclusive, at the time of signing the informed consent, regardless of gender. 2. Subjects with unilateral hemiplegia due to stroke (with a time interval of ≥ 3 months from stroke onset to randomized enrollment) exhibiting upper limb spasticity. 3. Subjects with Disability Assessment Scale score of at least 2 on the Principal Target of Treatment (one of four functional domains: hygiene, dressing, limb position and pain). 4. If taking oral antispasticity, the dosage must be stable for at least 1 month prior to randomized enrollment. 5. If the study limb receives physical therapy or occupational therapy, the frequency, type, and intensity must be stable for at least 3 weeks prior to randomized enrollment. Exclusion Criteria: 1. History of allergy to any component of the experimental drugs. 2. Previous use of any botulinum toxin within 6 months prior to randomized enrollment, or plan to use other botulinum toxins not specified in the study protocol during the study. 3. Fixed contractures of the studied limb. 4. Any medical condition that may increase the risk to the subject when using Botulinum Toxin Type A. 5. Need for treatment with drugs that interfere with neuromuscular function during the study. 6. Plan or anticipate to use new antispasticity drugs during the study. 7. History of epilepsy. 8. Pregnant or breastfeeding women. 9. Participation in other drug/device clinical trials within 1 month prior to randomized enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Upper limb spasticity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Upper limb spasticity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anhui Provincial Hospital

    RECRUITING

    Hefei, Anhui, China

  • Chongqing Traditional Chinese Medicine Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, China

  • Huai'an First People's Hospital

    RECRUITING

    Huai'an, Jiangsu, China

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Qilu Hospital of Shandong University

    RECRUITING

    Qingdao, Shandong, China

  • RenMin Hospital Of Wuhan University

    RECRUITING

    Wuhan, Hubei, China

  • Rui Jin Hospital of Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Shanghai Fudan University HuaShan Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Shanxi Bethune Hospital

    RECRUITING

    Taiyuan, Shanxi, China

  • Shanxi provincial people's Hospital

    RECRUITING

    Taiyuan, Shanxi, China

  • Shenzhen Second People's Hospital

    RECRUITING

    Shenzhen, Guangdong, China

  • Sun Yat-sen Memorial Hospital

    RECRUITING

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Henan University

    RECRUITING

    Kaifeng, Henan, China

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, China

  • The Fourth Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, China

  • The Second Affiliated Hospital of Kunming Medical University

    RECRUITING

    Kunming, Yunnan, China

  • The Second People's Hospital of Hefei

    RECRUITING

    Hefei, Anhui, China

  • Tianjin Medical University General Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

  • West China Hospital，Sichuan University

    RECRUITING

    Chengdu, Sichuan, China

  • Xuzhou Medical University Affiliated Hospital

    RECRUITING

    Xuzhou, Jiangsu, China

  • Yangzhi Affiliated Rehabilitation Hospital of Tongji University

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Zibo Municipal Hospital

    RECRUITING

    Zibo, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.